Chezi Ganzel

Jerusalem, JM, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Exploring variables leading to major postmarketing label changes in leading regulatory authorities: a retrospective cohort study in Israel.

Exploring variables leading to major postmarketing label changes in leading regulatory authorities: a retrospective cohort study in Israel.

Journal: BMJ open

Published: August 11, 2026

Cladribine-based salvage therapy in relapsed/refractory AML: A multicenter retrospective study.

Cladribine-based salvage therapy in relapsed/refractory AML: A multicenter retrospective study.

Journal: Leukemia research

Published: June 07, 2026

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials.

Journal: Haematologica

Published: May 04, 2026

Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML.

Subclinical Cardiac Changes Following CPX-351 Induction in Adults with Favorable/Intermediate-Risk AML.

Journal: EJHaem

Published: March 19, 2026

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

Journal: British journal of haematology

Published: September 30, 2024

Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

Journal: European journal of haematology

Published: August 29, 2024

Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Journal: Bone marrow transplantation

Published: July 18, 2024

Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.

Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.

Journal: Blood advances

Published: June 17, 2024

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.

Journal: British journal of haematology

Published: March 27, 2024

Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Journal: Bone marrow transplantation

Published: August 07, 2023

Successful Treatment with Daratumumab of a Patient with Monoclonal Lambda Light Chain Disease Presenting as Nephrotic Syndrome and Crescentic Glomerulonephritis.

Successful Treatment with Daratumumab of a Patient with Monoclonal Lambda Light Chain Disease Presenting as Nephrotic Syndrome and Crescentic Glomerulonephritis.

Journal: Acta haematologica

Published: July 27, 2023

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.

Journal: Blood advances

Published: June 12, 2023

Showing 1-12 of 72

Last Updated: 09/26/2026